|Videos|May 20, 2021
The Oncotype DX Breast Recurrence Score: Clinical Trial Data
Author(s)Debu Tripathy, MD
Results of 2 prospective, randomized clinical trials of the Oncotype DX Breast Recurrence Score and implications for practice.
Advertisement
Episodes in this series
Advertisement
Related to this article
Xiuning Le, MD, PhD, weighs sevabertinib against zongertinib and trastuzumab deruxtecan in HER2-mutant non–small cell lung cancer.
A prospective, multicenter study found that a blood-based miRNA assay combined with CA19-9 improved early detection of pancreatic ductal adenocarcinoma.
Final 5-year IMCgp100-202 data show tebentafusp improved OS vs investigator’s choice in untreated HLA-A*02:01–positive metastatic uveal melanoma.
The FDA granted platform technology designation to the immunotherapeutic platform for use in HPV-positive cancers such as head and neck, cervical, and anal.
An end-of-phase 1 meeting was supported by phase 1b data showing efficacy with LYT-220 among relapsed/refractory myelodysplastic syndrome groups.
Beth Erickson, MD, FACR, FASTRO, FABS, discussed pioneering MRI-guided brachytherapy at MCW and her priorities as incoming ASTRO president-elect.
The updated NCCN Guidelines for myeloproliferative neoplasms recommend rusfertide as a category 1 option across both low- and high-risk polycythemia vera.
As part of the ANDA pathway, Bravnetsa is the only radiopharmaceutical the FDA has determined to be bioequivalent and therapeutically equivalent to the reference product, Lutathera.
Advertisement
Advertisement
Trending on CancerNetwork
1
Lutetium Lu 177 Dotatate Biosimilar Earns Final FDA Approval in GEP-NETs
2
Rusfertide Earns Category 1 NCCN Recommendation in Polycythemia Vera
3
PANXEON Liquid Biopsy Demonstrates Potential for Detecting Early Pancreatic Cancer
4
Novel Monoclonal Antibody Wins FDA Fast Track Designation in High-Risk MDS
5